Education
About Us
Working with TipRanks
Follow Us
Verastem (VSTM)
NASDAQ:VSTM
VSTM Stock Chart & Stats
$6.41
-$0.30(-4.59%)
At close: 4:00 PM EST
$6.41
-$0.30(-4.59%)
Day’s Range― - ―
52-Week Range$4.01 - $11.25
Previous CloseN/A
Volume547.29K
Average Volume (3M)1.84M
Market Cap
$469.24M
Enterprise Value$339.82M
Total Cash (Recent Filing)$137.71M
Total Debt (Recent Filing)$89.48M
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Mar 12, 2026EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.35
Shares Outstanding75,319,800
10 Day Avg. Volume1,655,988
30 Day Avg. Volume1,842,866
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)-6.39
Price to Sales (P/S)18.46
P/FCF Ratio-1.76
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue25.40
Enterprise Value/Gross Profit30.17
Enterprise Value/Ebitda-1.42
Forecast
1Y Price Target
$15.60Price Target Upside143.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Potential - VS-7375Early clinical data position VS-7375 as a potentially best-in-class KRAS G12D inhibitor with improved tolerability and promising efficacy, suggesting meaningful upside if forthcoming US study data confirm activity.
Commercial PerformanceFirst full quarter net product revenue for Avmapki Fakzynja co-pack reached 11.2 million, exceeding consensus expectations and validating early physician adoption, which could support further market penetration.
Financial Runway And Upcoming CatalystsGuidance for a cash runway into the second half of 2026 combined with multiple expected near-term clinical and commercial milestones could reduce financing risk and serve as material catalysts for the stock.
Bears Say
Confirmatory Trial Enrollment RiskRequirement to add 29 additional patients to the confirmatory RAMP-301 study introduces execution risk and could delay pivotal readouts and regulatory progress.
Guideline And Reimbursement UncertaintyUncertainty about the timing of AF's inclusion in updated NCCN treatment guidelines may impede reimbursement and slow broader commercial uptake.
Program DiscontinuationDiscontinuation of the RAMP 203 KRAS G12C combination program narrows the pipeline and reduces exposure to the larger G12C market, increasing reliance on the KRAS G12D program for growth.
Verastem News
VSTM FAQ
What was Verastem’s price range in the past 12 months?
Verastem lowest stock price was $4.01 and its highest was $11.24 in the past 12 months.
What is Verastem’s market cap?
Verastem’s market cap is $469.24M.
When is Verastem’s upcoming earnings report date?
Verastem’s upcoming earnings report date is Mar 12, 2026 which is in 41 days.
How were Verastem’s earnings last quarter?
Verastem released its earnings results on Nov 04, 2025. The company reported -$1.35 earnings per share for the quarter, missing the consensus estimate of -$0.617 by -$0.733.
Is Verastem overvalued?
According to Wall Street analysts Verastem’s price is currently Undervalued.
Does Verastem pay dividends?
Verastem does not currently pay dividends.
What is Verastem’s EPS estimate?
Verastem’s EPS estimate is -0.52.
How many shares outstanding does Verastem have?
Verastem has 75,319,800 shares outstanding.
What happened to Verastem’s price movement after its last earnings report?
Verastem reported an EPS of -$1.35 in its last earnings report, missing expectations of -$0.617. Following the earnings report the stock price went down -20.101%.
Which hedge fund is a major shareholder of Verastem?
Currently, no hedge funds are holding shares in VSTM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Verastem Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.60 (143.37% Upside)
$15.60 (143.37% Upside)
Blogger Sentiment
Bullish
VSTM Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 291.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $134.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 3.2%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.30%
12-Months-Change
Fundamentals
Return on Equity
-2888.70%
Trailing 12-Months
Asset Growth
39.94%
Trailing 12-Months
Company Description
Verastem
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
VSTM Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted successful product launch and strong financial positioning, with significant revenue generation and advancements in clinical trials. However, continued expenses and the need for additional trial enrollment present challenges.View all VSTM earnings summariesVSTM Stock 12 Month Forecast
Average Price Target
$15.60
▲(143.37% Upside)
Technical Analysis
Cardiff Oncology
―
Mereo Biopharma Group Plc
―
Monopar Therapeutics Inc
―
Silence Therapeutics
―
Atea Pharmaceuticals
―
Ownership Overview
1.08% Insiders
6.34% Mutual Funds
40.78% Other Institutional Investors
40.06% Public Companies and
Individual Investors